New eye drops aim to soothe dry eyes

NCT ID NCT05486728

Completed Symptom relief Sponsor: Dreamhawk Vision Biotech, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This Phase 2 trial tested an experimental eye drop called SHJ002 in 85 adults with dry eye disease. The drops are designed to block a specific microRNA linked to inflammation. Researchers measured changes in corneal staining and symptom scores over 84 days to see if the drops are safe and effective compared to a placebo.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: SHJ002 (antisense oligonucleotide eye drops)
What this could lead to: If successful, this could lead to a new eye drop treatment that reduces dry eye symptoms and corneal damage.
What could go wrong: This is an early Phase 2 trial with only 85 people. The drug may not work better than placebo, and long-term safety is unknown.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DRY EYE DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

dry eye syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

DRY EYE DISEASE

Contacts and locations

Locations

Australian Eye Specialists

Werribee, Victoria, 3030, Australia
Kaohsiung Veterans General Hospital

Kaohsiung City, Kaohsiung, 813414, Taiwan
King Chulalongkorn Memorial Hospital

Bangkok, 10330, Thailand
Ramathibodi Hospital, Mahidol University

Bangkok, 10400, Thailand

More trials for these conditions

Other studies related to the condition(s) this trial covers.